Ronald Blue Trust, Inc. Exelixis, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.98 Billion
- Q3 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 6,094 shares of EXEL stock, worth $209,938. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,094
Previous 3,953
54.16%
Holding current value
$209,938
Previous $88,000
79.55%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding EXEL
# of Institutions
498Shares Held
244MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.01 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$875 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$529 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$394 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.1B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...